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These guidelines are intended for use by infectious disease specialists, orthopedic surgeons, neurosurgeons, ra-
diologists, and other healthcare professionals who care for patients with native vertebral osteomyelitis (NVO).
They include evidence and opinion-based recommendations for the diagnosis and management of patients with
NVO treated with antimicrobial therapy, with or without surgical intervention.
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EXECUTIVE SUMMARY
Native vertebral osteomyelitis (NVO) in adults is often
the result of hematogenous seeding of the adjacent disc
space from a distant focus, as the disc is avascular [1, 2].
The diagnosis of NVO can often be delayed several
months and may initially be misdiagnosed and mis-
managed as a degenerative process [3, 4]. NVO is typi-
cally diagnosed in the setting of recalcitrant back pain
unresponsive to conservative measures and elevated in-
ﬂammatory markers with or without fever. Plain
radiographs of the spine are not sensitive for the early
diagnosis of NVO. Magnetic resonance imaging (MRI)
of the spine is often required to establish the diagnosis.
Except in septic patients or patients with neurologic
compromise, empiric antimicrobial therapy should be
withheld, when possible, until a microbiologic diagno-
sis is conﬁrmed. An image-guided or intraoperative as-
piration or biopsy of a disc space or vertebral endplate
sample submitted for microbiologic and pathologic
examination often establishes the microbiologic or
pathologic diagnosis of NVO [5]. NVO is commonly
monomicrobial and most frequently due to Staphylo-
coccus aureus [6–8]. The concomitant presence of
S. aureus bloodstream infection within the preceding
3 months and compatible spine MRI changes preclude
the need for a disc space aspiration in most patients
[1, 9, 10]. Deﬁnitive therapy should be based on the re-
sults of culture and in vitro susceptibility testing. The
majority of patients are cured with a 6-week course of
antimicrobial therapy, but some patients may need
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surgical debridement and/or spinal stabilization during or after
a course of antimicrobial therapy [7, 11–13]. Indications for sur-
gery may include the development of neurologic deﬁcits or
symptoms of spinal cord compression and evidence of progres-
sion or recurrence despite proper antimicrobial therapy [6].
Most patients can be followed symptomatically and by monitor-
ing laboratory parameters such as C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR) [14]. Repeat imaging
studies should be reserved for patients failing to show clinical
and or laboratory improvement [15, 16].
Summarized below are the Infectious Diseases Society of
America (IDSA) recommendations pertaining to the diagnosis
and management of patients with NVO. The expert panel fol-
lowed a process used in the development of other IDSA guide-
lines, which included a systematic weighting of the strength of
recommendation and quality of evidence using the GRADE
(Grading of Recommendations Assessment, Development and
Evaluation) system [17–20] (Table 1). A detailed description
of the methods, background, and evidence summaries that sup-
port each of the recommendations can be found online in the
full text of the guidelines.
RECOMMENDATIONS FOR CLINICAL
DIAGNOSTICS
I. When Should the Diagnosis of NVO Be Considered?
Recommendations
1. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and fever (strong,
low).
2. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and elevated ESR
or CRP (strong, low).
3. Clinicians should suspect the diagnosis of NVO in patients
with new or worsening back or neck pain and bloodstream
infection or infective endocarditis (strong, low).
4. Clinicians may consider the diagnosis of NVO in patients
who present with fever and new neurologic symptoms with
or without back pain (weak, low).
5. Clinicians may consider the diagnosis of NVO in patients
who present with new localized neck or back pain, following
a recent episode of Staphylococcus aureus bloodstream infec-
tion (weak, low).
II. What Is the Appropriate Diagnostic Evaluation of Patients With
Suspected NVO?
Recommendations
6. We recommend performing a pertinent medical and motor/
sensory neurologic examination in patients with suspected
NVO (strong, low).
7. We recommend obtaining bacterial (aerobic and anaerobic)
blood cultures (2 sets) and baseline ESR and CRP in all pa-
tients with suspected NVO (strong, low).
8. We recommend a spine MRI in patients with suspected
NVO (strong, low).
9. We suggest a combination spine gallium/Tc99 bone scan, or
computed tomography scan or a positron emission tomogra-
phy scan in patients with suspected NVO when MRI cannot
be obtained (eg, implantable cardiac devices, cochlear implants,
claustrophobia, or unavailability) (weak, low).
10. We recommend obtaining blood cultures and serologic
tests for Brucella species in patients with subacute NVO re-
siding in endemic areas for brucellosis (strong, low).
11. We suggest obtaining fungal blood cultures in patients with
suspected NVO and at risk for fungal infection (epidemio-
logic risk or host risk factors) (weak, low).
12. We suggest performing a puriﬁed protein derivative (PPD)
test or obtaining an interferon-γ release assay in patients with
subacute NVO and at risk for Mycobacterium tuberculosis
NVO (ie, originating or residing in endemic regions or hav-
ing risk factors) (weak, low).
13. In patients with suspected NVO, evaluation by an infec-
tious disease specialist and a spine surgeon may be consid-
ered (weak, low).
III. When Should an Image-Guided Aspiration Biopsy or
Additional Workup Be Performed in Patients With NVO?
Recommendations
14. We recommend an image-guided aspiration biopsy in pa-
tients with suspected NVO (based on clinical, laboratory, and
imaging studies) when a microbiologic diagnosis for a known
associated organism (S. aureus, Staphylococcus lugdunensis,
and Brucella species) has not been established by blood cul-
tures or serologic tests (strong, low).
15. We advise against performing an image-guided aspiration bi-
opsy in patients with S. aureus, S. lugdunensis, or Brucella spe-
cies bloodstream infection suspected of having NVO based on
clinical, laboratory, and imaging studies (strong, low).
16. We advise against performing an image-guided aspiration
biopsy in patients with suspected subacute NVO (high en-
demic setting) and strongly positive Brucella serology
(strong, low).
IV. How Long Should Antimicrobial Therapy Be Withheld Prior to
an Image-Guided Diagnostic Aspiration Biopsy in Patients With
Suspected NVO?
Recommendations
17. In patients with neurologic compromise with or without
impending sepsis or hemodynamic instability, we recom-
mend immediate surgical intervention and initiation of em-
piric antimicrobial therapy (strong, low).
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V. When Is It Appropriate to Send Fungal, Mycobacterial, or
Brucellar Cultures or Other Specialized Testing Following an
Image-Guided Aspiration Biopsy in Patients With Suspected NVO?
Recommendations
18. We suggest the addition of fungal, mycobacterial, or bru-
cellar cultures on image-guided biopsy and aspiration speci-
mens in patients with suspected NVO if epidemiologic, host
risk factors, or characteristic radiologic clues are present
(weak, low).
19. We suggest the addition of fungal and mycobacterial cul-
tures and bacterial nucleic acid ampliﬁcation testing to ap-
propriately stored specimens if aerobic and anaerobic
bacterial cultures reveal no growth in patients with suspected
NVO (weak, low).
Table 1. Strength of Recommendations and Quality of the Evidence
Strength of
Recommendation and
Quality of Evidence
Clarity of Balance Between
Desirable and Undesirable
Effects
Methodological Quality of
Supporting Evidence (Examples) Implications
Strong recommendation,
high-quality evidence
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Consistent evidence from well-
performed
RCTs or exceptionally strong
evidence from unbiased
observational studies
Recommendation can apply to most
patients in most circumstances.
Further research is unlikely to change
our confidence in the estimate of
effect.
Strong recommendation,
moderate-quality
evidence
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Evidence from RCTs with important
limitations (inconsistent results,
methodological flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies
Recommendation can apply to most
patients in most circumstances.
Further research (if performed) is
likely to have an important impact on
our confidence in the estimate of
effect and may change the estimate.
Strong recommendation,
low-quality quality
evidence
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Evidence for at least 1 critical
outcome from observational
studies, RCTs with serious flaws
or indirect evidence
Recommendation may change when
higher-quality evidence becomes
available. Further research (if
performed) is likely to have an
important impact on our confidence
in the estimate of effect and is likely
to change the estimate.
Strong recommendation,
very-low-quality evidence
(very rarely applicable)
Desirable effects clearly
outweigh undesirable
effects, or vice versa
Evidence for at least 1 critical
outcome from unsystematic
clinical observations or very
indirect evidence
Recommendation may change when
higher-quality evidence becomes
available; any estimate of effect for at
least 1 critical outcome is very
uncertain.
Weak recommendation,
high-quality evidence
Desirable effects closely
balanced with undesirable
effects
Consistent evidence from well-
performed
RCTs or exceptionally strong
evidence from unbiased
observational studies
The best action may differ depending
on circumstances or patients or
societal values. Further research is
unlikely to change our confidence in
the estimate of effect.
Weak recommendation,
moderate-quality
evidence
Desirable effects closely
balanced with undesirable
effects
Evidence from RCTs with important
limitations (inconsistent results,
methodological flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies
Alternative approaches likely to be
better for some patients under some
circumstances. Further research (if
performed) is likely to have an
important impact on our confidence
in the estimate of effect and may
change the estimate.
Weak recommendation,
low-quality evidence
Uncertainty in the estimates of
desirable effects, harms, and
burden; desirable effects,
harms, and burden may be
closely balanced
Evidence for at least 1 critical
outcome from observational
studies or from RCTs with serious
flaws or indirect evidence
Other alternatives may be equally
reasonable. Further research is very
likely to have an important impact on
our confidence in the estimate of
effect and is likely to change the
estimate.
Weak recommendation,
very low-quality evidence
Major uncertainty in the
estimates of desirable
effects, harms, and burden;
desirable effects may or may
not be balanced with
undesirable effects
Evidence for at least 1 critical
outcome from unsystematic
clinical observations or very
indirect evidence
Other alternatives may be equally
reasonable. Any estimate of effect,
for at least 1 critical outcome, is very
uncertain.
Abbreviation: RCT, randomized controlled trial.
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VI. When Is It Appropriate to Send the Specimens for Pathologic
Examination Following an Image-Guided Aspiration Biopsy in
Patients With Suspected NVO?
Recommendation
20. If adequate tissue can be safely obtained, pathologic spec-
imens should be sent from all patients to help conﬁrm a di-
agnosis of NVO and guide further diagnostic testing,
especially in the setting of negative cultures (strong, low).
VII. What Is the Preferred Next Step in PatientsWith Nondiagnostic
Image-Guided Aspiration Biopsy and Suspected NVO?
Recommendations
21. In the absence of concomitant bloodstream infection, we
recommend obtaining a second aspiration biopsy in patients
with suspected NVO in whom the original image-guided
aspiration biopsy specimen grew a skin contaminant (coag-
ulase-negative staphylococci [except S. lugdunensis], Propio-
nibacterium species, or diphtheroids) (strong, low).
22. In patients with a nondiagnostic ﬁrst image-guided aspira-
tion biopsy and suspected NVO, further testing should be
done to exclude difﬁcult-to-grow organisms (eg, anaerobes,
fungi, Brucella species, or mycobacteria) (strong, low).
23. In patients with suspected NVO and a nondiagnostic image-
guided aspiration biopsy and laboratory workup, we suggest
either repeating a second image-guided aspiration biopsy, per-
forming percutaneous endoscopic discectomy and drainage
(PEDD),orproceedingwithanopenexcisionalbiopsy(weak, low).
RECOMMENDATIONS FOR CLINICAL THERAPY
VIII. When Should Empiric Antimicrobial Therapy Be Started in
Patients With NVO?
Recommendations
24. In patients with normal and stable neurologic examination
and stable hemodynamics, we suggest holding empiric anti-
microbial therapy until a microbiologic diagnosis is estab-
lished (weak, low).
25. In patients with hemodynamic instability, sepsis, septic
shock, or severe or progressive neurologic symptoms, we sug-
gest the initiation of empiric antimicrobial therapy in con-
junction with an attempt at establishing a microbiologic
diagnosis (weak, low).
IX. What Is the Optimal Duration of Antimicrobial Therapy in
Patients With NVO?
Recommendations
26. We recommend a total duration of 6 weeks of parenteral
or highly bioavailable oral antimicrobial therapy for most
patients with bacterial NVO (strong, low).
27. We recommend a total duration of 3 months of antimicro-
bial therapy for most patients with NVO due to Brucella
species (strong, moderate).
X. What Are the Indications for a Surgical Intervention in Patients
With NVO?
Recommendations
28. We recommend surgical intervention in patients with pro-
gressive neurologic deﬁcits, progressive deformity, and spinal
instability with or without pain despite adequate antimicro-
bial therapy (strong, low).
29. We suggest surgical debridement with or without stabiliza-
tion in patients with persistent or recurrent bloodstream in-
fection (without alternative source) or worsening pain
despite appropriate medical therapy (weak, low).
30. We advise against surgical debridement and/or stabilization
in patients who have worsening bony imaging ﬁndings at 4–6
weeks in the setting of improvement in clinical symptoms,
physical examination, and inﬂammatory markers (weak, low).
RECOMMENDATIONS FORCLINICAL FOLLOW-UP
XI. How Should Failure of Therapy Be Deﬁned in Treated Patients
With NVO?
Recommendation
31. We suggest that persistent pain, residual neurologic deﬁ-
cits, elevated markers of systemic inﬂammation, or radio-
graphic ﬁndings alone do not necessarily signify treatment
failure in treated NVO patients (weak, low).
XII. What Is the Role of Systemic Inﬂammatory Markers and MRI
in the Follow-up of Treated Patients With NVO?
Recommendations
32. We suggest monitoring systemic inﬂammatory markers
(ESR and or CRP) in patients with NVO after approximately
4 weeks of antimicrobial therapy, in conjunction with a clin-
ical assessment (weak, low).
33. We recommend against routinely ordering follow-up MRI
in patients with NVO in whom a favorable clinical and lab-
oratory response to antimicrobial therapy was observed
(strong, low).
34. We suggest performing a follow-up MRI to assess evolu-
tionary changes of the epidural and paraspinal soft tissues
in patients with NVO who are judged to have a poor clinical
response to therapy (weak, low).
XIII. How Do You Approach a Patient With NVO and Suspected
Treatment Failure?
Recommendations
35. In patients with NVO and suspected treatment failure, we
suggest obtaining markers of systemic inﬂammation (ESR
and CRP). Unchanged or increasing values after 4 weeks of
treatment should increase suspicion for treatment failure
(weak, low).
36. We recommend obtaining a follow-up MRI with emphasis
on evolutionary changes in the paraspinal and epidural soft
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tissue ﬁndings in patients with NVO and suspected treat-
ment failure (strong, low).
37. In patients with NVO and clinical and radiographic
evidence of treatment failure, we suggest obtaining additional
tissue samples for microbiologic (bacteria, fungal, and myco-
bacterial) and histopathologic examination, either by image-
guided aspiration biopsy or through surgical sampling (weak,
very low).
38. In patients with NVO and clinical and radiographic evi-
dence of treatment failure, we suggest consultation with a
spine surgeon and an infectious disease physician (weak,
very low).
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